Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Cantor sticking with their Buy and $9 price target

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon Feb 28, 2023 1:57pm

51 Views

Post# 35310348

RE:RE:Cantor sticking with their Buy and $9 price target

The Q3 MD&A said it was progressing as planned, so nothing at that point. It was really glossed over today, but if you look at the MD&A that was posted today it mentions the 6 month delay.

I really question this team's ability to execute on anything if they struggle to comnplete a simple HFS in a year.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand